Phase I-II Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for Non-Small Cell Lung Cancer

Phase I-II Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for Non-Small Cell Lung Cancer - Phase I-II Study of Irinotecan and Erlotinib in Patients with Erlotinib Failure for Non-Small Cell Lung Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000003102

Enrollment

Registered

2010-01-27

Start date

2010-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erlotinib Failure for Non-Small Cell Lung Cancer

Interventions

Ilinotecan and Erlotinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Erlotinib Failure for Non-Small Cell Lung Cancer.

Exclusion criteria

Exclusion criteria: Clinically significant serious disease

Design outcomes

Primary

Measure	Time frame
DLT and RD on Phase I RR on Phase II	—

Countries

Japan

Contacts

Public ContactAtsushi Horiike

CancernInstitute Hospital Thoracic Medical Oncology

atsushi.horiike@jfcr.or.jp03-3520-0111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026